Melody Chang, R.Ph., says payers cover bispecific and CAR-T drugs but not the monitoring that lets community practices deliver them safely at lower cost.
|Podcasts|November 16, 2022
Using the 'Pathway' Approach to Shorten the Time Between Cancer Diagnosis and Treatment
Author(s)Briana Contreras
In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.
Advertisement
To listen to more episodes featured on Tuning Into The C-Suite, visit us on
Advertisement
Related to this article
American Oncology Network’s Melody Chang, R.Ph., says 18% of its first 70 outpatient bispecific patients had CRS, all low grade with no hospitalizations.
Reimagine Care's CEO says one-off hospital approvals slow CAR-T access and urges buyers to ask vendors to prove outcomes such as avoided ED visits.
Continuous glucose monitoring cut mean A1C from 8.8% to 7.2% over 26 weeks in adults with type 2 diabetes not on insulin, 0.9 points more than routine care in the CONNECT trial.
A screening program in eight countries found early-stage type 1 diabetes in about 1 in 350 children with no family history of the disease.
Healthcare leaders should be preparing now for important changes in prior authorization and other areas of healthcare.
UC Davis Health’s Tiffany Phung, Pharm.D., and Tim Cutler, Pharm.D., say staff-driven ideas protect research independence in industry partnerships.
UC Davis Health’s Tiffany Phung, Pharm.D., and Tim Cutler, Pharm.D., say research justifies services and opens doors to limited distribution drugs.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Apothecary Pharma recalls compounded tirzepatide and NAD+ vials over sterility concerns
2
More checks in the plus column for GLP-1s for obstructive sleep apnea | CHEST 2026
3
Algia Pharma completes investigational drug toxicology study for non-opioid acute pain regimen AlgiaPak
4
Rex Hoffman, M.D., on how a CMO balances competing priorities | HSES 2026
5